US Medical Community Continues to Utilize Nitric Oxide Tests for Airway Inflammation Assessment.
US Nitric Oxide Test Market News
Recent news concerning nitric oxide (NO) tests in the US primarily revolves around its established clinical utility, particularly in the diagnosis and management of asthma, and emerging research in other areas like COVID-19 treatment.
Established Use in Asthma Management:
The fractional exhaled nitric oxide (FeNO) test remains a key tool for allergists and pulmonologists in the US to assess airway inflammation, a hallmark of asthma. News outlets and medical resources consistently highlight its use in:
Diagnosing asthma, especially in cases with atypical symptoms or when combined with other pulmonary function tests like spirometry. Elevated FeNO levels can indicate the presence of eosinophilic asthma, a subtype that often responds well to corticosteroid treatment.
Monitoring asthma control and the effectiveness of inhaled corticosteroid therapy. Lowering FeNO levels often correlate with reduced airway inflammation due to medication.
Identifying patients who are more likely to benefit from inhaled corticosteroids.
Evaluating chronic cough to determine if airway inflammation is a contributing factor.
Major medical organizations like the American Lung Association and the National Jewish Health provide readily accessible information about the FeNO test, its procedure, and interpretation of results, indicating its established place in respiratory medicine in the US. Portable devices for FeNO testing are increasingly available in clinics and hospitals.
Emerging Research in COVID-19:
More recently, research has explored the potential of inhaled nitric oxide as a therapy for patients with severe respiratory failure due to COVID-19 pneumonia.
A multicenter international phase II clinical trial led by investigators at Massachusetts General Hospital and the University of Alabama at Birmingham showed that high-dose inhaled nitric oxide improved oxygenation and reduced the risk of long-term neurological symptoms in ventilated COVID-19 patients. The study also suggested potential antiviral activity of nitric oxide against SARS-CoV-2.
Ohio State University also conducted trials testing a novel inhaled nitric oxide therapy for COVID-19 patients, aiming to reduce the need for mechanical ventilation and improve recovery times.
Further analysis of the aforementioned multicenter trial indicated that high-dose inhaled nitric oxide may be particularly beneficial in reducing the risk of death among critically ill Black patients with COVID-19, a finding potentially linked to differences in baseline nitric oxide systems across racial groups.
While these findings are promising, further research, including larger phase III trials, is needed to solidify the role of inhaled nitric oxide as a standard treatment for COVID-19-related respiratory failure.
Other Potential Applications:
Older news from institutions like MIT highlighted the development of novel methods for nitric oxide detection, which could have implications for understanding its role in neurological signaling and other biological functions. While not directly related to current widespread clinical testing, such research underscores the ongoing interest in the multifaceted roles of nitric oxide in the body.
In summary, current news regarding nitric oxide testing in the US emphasizes its well-established role in asthma diagnosis and management through the FeNO test, alongside emerging research exploring the therapeutic potential of inhaled nitric oxide in the context of COVID-19.